Notably, the survival trend associated with dupilumab was protective of mortality but did not reach statistical significance in this study due to insufficient sample size of the dupilumab population to demonstrate this protective effect.
← all excerpts
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events.
1
—
—